Niyaz Ahmad Naikoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Niyaz Ahmad Naikoo has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Roohi Rasool
Department of Immunology and Molecular Medicine, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir 190011, India
4 shared publicationsSonaullah Shah
Department of General Medicine, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir 190011, India
4 shared publications- Bashir Ahmad Ganai
Centre of Research for Development, University of Kashmir, Srinagar 190006, India
3 shared publications Iqbal Qasim
Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences, Soura Srinagar, Kashmir
3 shared publicationsDil Afroze
Department of Immunology and Molecular Medicine, Sher-I-Kashmir Institute of Medical Sciences, Soura Srinagar, Kashmir
2 shared publicationsIqra Hameed
2 shared publications
Latest Publications
- 1 April 2021
- Published by Elsevier in Cancer Genetics
- Vol. 252-253, 96-106
Promoter hypermethylation regulates vitamin D receptor (VDR) expression in colorectal cancer-A study from Kashmir valley
- 1 April 2021
- Published by Elsevier in Cancer Genetics
- Vol. 252-253, 96-106
Promoter hypermethylation regulates vitamin D receptor (VDR) expression in colorectal cancer-A study from Kashmir valley
- Open Access
- 21 August 2019
- Published by African Journals Online (AJOL) in African Health Sciences
- Vol. 19 (2) , 2121-2129
Modifiable and non-modifiable risk factors in ischemic stroke: a meta-analysis
Modifiable and non-modifiable risk factors in ischemic stroke: a meta-analysis
- 21 August 2019
- Published by African Journals Online (AJOL) in African Health Sciences
- Vol. 19 (2) , 2121-2129
Open AccessModifiable and non-modifiable risk factors in ischemic stroke: a meta-analysis
Modifiable and non-modifiable risk factors in ischemic stroke: a meta-analysis
- 1 October 2017
- Published by Elsevier in Cancer Genetics
- Vol. 216-217, 67-73
Upregulation of vascular endothelial growth factor (VEGF), its role in progression and prognosis of non-small cell lung carcinoma
- 1 October 2017
- Published by Elsevier in Cancer Genetics
- Vol. 216-217, 67-73
Upregulation of vascular endothelial growth factor (VEGF), its role in progression and prognosis of non-small cell lung carcinoma
- Open Access
- 1 July 2017
- Vol. 18 (7) , 1799-1804
SNP and Haplotype Analysis of Vascular Endothelial Growth Factor (VEGF) Gene in Lung Cancer Patients of Kashmir
- 1 July 2017
- Vol. 18 (7) , 1799-1804
Open AccessSNP and Haplotype Analysis of Vascular Endothelial Growth Factor (VEGF) Gene in Lung Cancer Patients of Kashmir
- Open Access
- 10 January 2016
- Published by Sciencedomain International in International Journal of Biochemistry Research & Review
- Vol. 15 (1) , 1-7
TNF-α (-308 G→A) Polymorphism and the Risk of Progression to End Stage Renal Disease in Nephropathy Patients
Aims: This hospital based case-control study sought to analyze the association between the promoter region polymorphism in TNF-α and the risks of developing end stage renal disease in nephropathy subjects. Methodology: 222 documented cases of end stage renal disease (Males=148, Females=74) subjects and 250 healthy controls (Males=130, Females=120) were included in the study. Among 222 cases, 126 subjects had hypertensive nephropathy and 96 had glomerulonephritis as contributing factors of ESRD. Clinical and demographic data was collected from each case. TNF-α (-308 G→A) promoter polymorphism was analyzed by selective amplification by polymerase chain reaction and subsequent digestion by NcoI restriction enzyme. Genotypic and allelic frequencies were compared to controls using Chi-square and Odds ratio analysis. Clinical parameters were compared across genotypes using logistic regression. The probability values were adjusted for age and gender. Results: Mean age of cases and controls was 47.78 and 46.83 years respectively. Genotypes for TNF-α -308 followed Hardy Weinberg equilibrium (P=0.17). The frequency of homozygous wild, heterozygous and homozygous rare genotypes in cases and controls was 62.6%, 31.08%, 6.3% and 74%, 23.6%, 2.4% respectively (P=0.019). Comparison of genotypes between cases and controls showed an association of AA genotype with ESRD (P=0.02, OR=3.1, 95%CI=1.1-6.2). The AA genotype was significantly associated with lower age in cases (P=0.008) as well as lower serum protein (P=0.03) and calcium levels (P=0.01). Conclusion: TNF-α (-308 G→A) promoter polymorphism is associated with nephropathy and the carriers of AA genotype exhibit an increased risk towards rapid progression of ESRD.
- 10 January 2016
- Published by Sciencedomain International in International Journal of Biochemistry Research & Review
- Vol. 15 (1) , 1-7
Open AccessTNF-α (-308 G→A) Polymorphism and the Risk of Progression to End Stage Renal Disease in Nephropathy Patients
Aims: This hospital based case-control study sought to analyze the association between the promoter region polymorphism in TNF-α and the risks of developing end stage renal disease in nephropathy subjects. Methodology: 222 documented cases of end stage renal disease (Males=148, Females=74) subjects and 250 healthy controls (Males=130, Females=120) were included in the study. Among 222 cases, 126 subjects had hypertensive nephropathy and 96 had glomerulonephritis as contributing factors of ESRD. Clinical and demographic data was collected from each case. TNF-α (-308 G→A) promoter polymorphism was analyzed by selective amplification by polymerase chain reaction and subsequent digestion by NcoI restriction enzyme. Genotypic and allelic frequencies were compared to controls using Chi-square and Odds ratio analysis. Clinical parameters were compared across genotypes using logistic regression. The probability values were adjusted for age and gender. Results: Mean age of cases and controls was 47.78 and 46.83 years respectively. Genotypes for TNF-α -308 followed Hardy Weinberg equilibrium (P=0.17). The frequency of homozygous wild, heterozygous and homozygous rare genotypes in cases and controls was 62.6%, 31.08%, 6.3% and 74%, 23.6%, 2.4% respectively (P=0.019). Comparison of genotypes between cases and controls showed an association of AA genotype with ESRD (P=0.02, OR=3.1, 95%CI=1.1-6.2). The AA genotype was significantly associated with lower age in cases (P=0.008) as well as lower serum protein (P=0.03) and calcium levels (P=0.01). Conclusion: TNF-α (-308 G→A) promoter polymorphism is associated with nephropathy and the carriers of AA genotype exhibit an increased risk towards rapid progression of ESRD.
- Open Access
- 20 December 2014
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 13 (1) , 1-6
CTTTA Deletion/Insertion polymorphism in 3'-UTR of LEPR gene in type 2 diabetes subjects belonging to Kashmiri population
Type 2 diabetes mellitus is a multi-factorial disease in which both genetic and non-genetic factors interact in order to precipitate the diabetic phenotype
- 20 December 2014
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 13 (1) , 1-6
Open AccessCTTTA Deletion/Insertion polymorphism in 3'-UTR of LEPR gene in type 2 diabetes subjects belonging to Kashmiri population
Type 2 diabetes mellitus is a multi-factorial disease in which both genetic and non-genetic factors interact in order to precipitate the diabetic phenotype